cisplatin,irinotecan,avelumab,domvanalimab,zimberelimab,sacituzumab govitecan,gemcitabine,sacituzumab govitecan,pembrolizumab
merck,otsuka,gilead sciences,pfizer,gilead,arcus biosciences
['muc ,(-much)', 'avelumab', 'pembro', 'sacituzumab', 'irinotecan', ' sg ', ' cis ', 'trophy,u-01', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'sacitu, govi', ' gem ', ' uc,(-ucsd),(-ucsf),']
trophy-u-01 cohort 2: sg in platinum-ineligible muc w/ prog post-cpi median prior anti-ca regiments: 2 (1-5) orr (pr/cr): 32% (0 cr). dor: 5.6 mo sd: 34% orr w/o prior platinum or ev exposure: 54% median pfs: 5.6 mo median os: 13.5 mo gr3+ ae: 68%
#gu23 
MD, MSc | @UofTUrology @SUO_YUO Fellow & @IHPMEUofT CEHCR PhD| Previously: @AUB_Lebanon and @MCG_Urology